Sensorion SA (ALSEN) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Sensorion SA €4.02, price €6.61, upside -39.2%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range €6.61 – €109.00 · fair‑value band €2.66 – €5.03 · the €6.61 price screens above the €4.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 4, 2026.
Follow Sensorion in your weekly email
Every Wednesday you see whether Sensorion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.
Show more
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.
Stock analysis
Sensorion SA (ALSEN) currently trades at €6.61, while our model-based Fair Value estimate is €4.02, 39.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Scenario range: €2.66 (bear) to €5.03 (bull), the price of €6.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sensorion SA reported revenue of €0 in FY2025 versus €4.3M in FY2021. Reported net income was −€29.4M in FY2025.
Key figures
Market cap €68.1M · P/S ratio 11.1 · EPS (TTM) €−4.49 · Return on equity −49.3% · Return on assets (EBIT) −49.6% · Operating margin −803% · Revenue (TTM) €6.2M · Revenue growth (YoY) +14.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 81% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −39%, ALSEN screens richer than that median.
Fair Value models
Bear €2.66Fair Value €4.02Bull €5.03
Price €6.61 · Upside -39.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.0%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.9%
’12
’13
’14
’15
’17
’18
’19
’20
’21
’22
’23
’24
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−542.1% (2019) → −426.9% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 607 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score37 · Below median
Fair Value upside−39.2% · Above median
Profitability
Return on assets−25.4% · Below median
Growth and dividend
Revenue growth14.7% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B1.72× · Pricier than median
P/S (TTM)12.46× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)74· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sensorion SA Fair Value". https://www.fairvalue-calculator.com/stock/ALSEN
Frequently asked questions
Is Sensorion SA (ALSEN) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of €4.02 versus a price of €6.61, about −39% upside (overvalued).
What is the fair value of ALSEN?
Our model-based fair value for Sensorion SA is €4.02 (as of Oct 4, 2026), built from audited fundamentals. The current price: €6.61.
What is the quality score of ALSEN?
Sensorion SA has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sensorion SA (ALSEN)?
Our model-based price target is the fair value of €4.02 (as of Oct 4, 2026) from 1 valuation models. Cautious scenario €2.66, optimistic scenario €5.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Sensorion SA stock forecast for 2026?
Our models put fair value at €4.02, about −39% upside versus a price of €6.61 (overvalued). Cautious scenario €2.66, optimistic scenario €5.03. The calculation is refreshed regularly with new filings.
What is the revenue of Sensorion SA (ALSEN)?
Sensorion SA reported trailing-twelve-month revenue of about €6.2M (latest available figure, as of Oct 4, 2026).
What is the intrinsic value of Sensorion SA (ALSEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sensorion SA it is €4.02 per share (as of Oct 4, 2026), against a price of €6.61. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Sensorion SA stock overvalued or undervalued in 2026?
As of Oct 4, 2026, ALSEN trades above its calculated fair value: price €6.61, fair value €4.02, a gap of about −39% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALSEN?
No. The price is what the market pays today (€6.61); the fair value is what the company's own numbers justify (€4.02). For Sensorion SA the two are €2.59 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sensorion SA worth?
The market values Sensorion SA at about €68.1M (market capitalisation, as of Oct 4, 2026). Per share that is €6.61; our models calculate a fair value of €4.02 per share.
What do the bullish and bearish scenarios say about ALSEN?
Our models span a range for Sensorion SA: cautious scenario €2.66, base €4.02, optimistic €5.03 per share (as of Oct 4, 2026, price €6.61). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sensorion SA (ALSEN)?
Balance-sheet figures for Sensorion SA (as of Oct 4, 2026): return on equity −49.3%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is ALSEN from its 52-week high?
Sensorion SA trades at €6.61, about 81% below its 52-week high of €35.00 and at the low of €6.61 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of €4.02 is for.
Which stocks are comparable to Sensorion SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sensorion SA stock attractive at the current price?
The data as of Oct 4, 2026: price €6.61, calculated fair value €4.02 (−39%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ALSEN calculated?
We run Sensorion SA through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €4.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Sensorion SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sensorion SA (ALSEN)?
The closing price on Oct 2, 2026 was €6.61. Our model-based fair value is €4.02, about −39% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sensorion SA right now?
The price sits above even our optimistic bull case (€5.03). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (€2.66 to €5.03) leaves room in how you read the outcome.
Key figures of Sensorion SA
How large is the market capitalisation of Sensorion SA (ALSEN)?
The market capitalisation of Sensorion SA is €68.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sensorion SA (ALSEN)?
The price-to-sales ratio of Sensorion SA is 11.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sensorion SA (ALSEN)?
Earnings per share at Sensorion SA are €−4.49. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sensorion SA (ALSEN)?
The return on equity (ROE) of Sensorion SA is −49.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sensorion SA (ALSEN)?
On an EBIT basis the return on assets of Sensorion SA is −49.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sensorion SA (ALSEN)?
The operating margin of Sensorion SA is −803% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sensorion SA (ALSEN)?
Revenue at Sensorion SA is growing +14.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sensorion SA (ALSEN) generate?
The free cash flow of Sensorion SA is −€27.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sensorion SA (ALSEN) hold?
Sensorion SA holds more cash than debt, €19.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sensorion SA in the live analysis
One click puts Sensorion SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
